∙ a.Patients with active RA having inadequate response to disease modifying antirheumatic drugs (DMARDs), including methotrexate (MTX) or b.Patients with severe, active and progressive RA not previously treated with MTX or other DMARDs c.Patients with severe, active AS who have responded inadequately to conventional therapy or d.Patients with active and progressive PsA when the response to previous DMARDs has been inadequate or e.Patients with moderate to severe plaque Ps who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultra-violet A.

• The Remsima® SC group will include all patients who meet one of the following classification at the time of enrolment:

‣ Biologic-naïve patients or

⁃ Patients continuing on infliximab IV including Remsima® IV who will switch to Remsima® SC or

⁃ Patients continuing on biologic treatments other than infliximab who will switch to Remsima® SC or

⁃ Patients continuing on Remsima® SC (having commenced Remsima® SC treatment prior to enrolment)

• The Remsima® IV group will include all patients who meet one of the following classification at the time of enrolment:

‣ Biologic-naïve patients or

⁃ Patients continuing on biologic treatments other than infliximab who will switch to Remsima® IV or

⁃ Patients continuing on infliximab IV including Remsima® IV who will switch to or maintain Remsima® IV \* Note: Switching from Remsima® SC to Remsima® IV is not allowed.